


JNJ REPORT



Equation of line of best fit: Price $\approx 0.64605 \cdot t + 206.298$

This graph shows the different probable outcomes of JNJ this coming year using more than 2 years of past recent data to come up with this graph. There are 15 total paths shown physically, but 1000's run outside of the scenes.

Final Price Mean : 223.03

Final Price Median : 219.80

Final Price P05 : 165.54

Final Price P25 : 195.40

Final Price P75 : 247.05

Final Price P95 : 292.87

JNJ REPORT

Now onto the next portion of this report, the article research:

JNJ is seen as a very stable stock over the past few years as seen by the model, and is predicted to continue rising in stability. JNJ, for the past few months, has been seen growing above the SMA for multiple types, which is beneficial for the stock and shows that JNJ has been a strong stock. However, that was likely because of JNJ's recent success in their business with products. According to The Motley Fool, "this month, the company received U.S. Food and Drug Administration (FDA) approval for the label expansion for several of its drug products". This shows the strength of JNJ when compared to other medical giants in the same field at this time of year.

You see, as good as JNJ is right now, it is unlikely that they will continue with this trend beyond December because they would need continued success in more drug products. Every strong and long-lasting stock has had strong months once in their history, at least. Looking at JNJ through a long-term lens is truly how to win in these markets, since this pharmaceutical giant should not be a quick buy/sell scenario. If you have invested in JNJ from the bottom, it wouldn't be a horrible time to sell as talked about above, but it is better to see it through and hold.

There is not really much evidence that JNJ will see a definite bearish pattern in the next coming months, so there isn't a real reason to sell all of your stock. According to Yahoo Finance, "In 2026, J&J expects accelerated growth in the Innovative Medicine segment to be driven by its key products as well as new drugs and recently launched products". This can be easy evidence to buy into JNJ even more since it is showing a business product plan for the new year.

Even through all this evidence that JNJ might see another good month, there are still some things that show the opposite. Some drug products of JNJ have been prone to biosimilars from competing companies, such as the drug Stelara, because of patents. This means that certain drug products might see future failure due to competing companies over a biosimilar. Including this competition, JNJ has also been in pursuit of a lawsuit for its baby products that have caused many cases relating to cancer. This lawsuit has started to heat up again as the year comes to a close since more cases are coming to light. Although JNJ did discontinue this product, that doesn't mean the effects went away to buyers since they are still existent.

Overall this stock has shown future growth and potential problems leading into the new year that either might stump or continue the bullish patterns we have seen from this month. In my opinion this stock is a HOLD.

JNJ REPORT

From this probability scenario, I derived a final price mean at the end of the year to be \$223.03. Keep in mind that this scenario doesn't take random bullish and bearish patterns into play and purely uses past data averages to come up with this mean. It doesn't take into account future projects and vaccines that JNJ will eventually come up with and cause the stock to rise. This is purely just the estimated value of the stock without the bullish pattern that has been going on for the past few months.

Let me run you down on some of the data gathered. The bottom 5% probable outcomes show a result of \$165.54 as the final closing price after a year. This definitely seems steep, because it is, this price shows the absolute lowest that JNJ prices will see in this scenario. However, on the higher scale, the top 5% probable outcomes show a result of \$292.87. This also seems steep (not taking into consideration the latest stock trend) for the same reason, this is the highest that the stock price will be in this scenario.

This model just shows the probability of a certain price happening through multiple scenarios that have nothing to do with sudden trends. It can be expressed that the current situation of JNJ is very good, but it is recommended that you HOLD or SELL a bit of your stock. This is because, although the stock mean is higher than the latest close, the stock has seen immense bullish patterns and will likely lower due to a mistake that JNJ might make. Holding is also a good decision since this model typically recommends people to hold on stocks with average volatilities since they will likely not have sudden changes in the stock. Selling parts of your stock is not a horrible decision because the model used for this data is ranging over multiple years, yet the price rose drastically over a couple of months, which is hard for the model to detect and take into consideration. This model simply is just measuring risks of the stock. That is why the overarching decision for this stock in the next year is to HOLD.

JNJ REPORT

Sources:

Miller, R. V. (2020, May 20). \$2 Billion Verdict Lead J&J to Settle Talcum Powder Lawsuits. Lawsuit Information Center Blog.

<https://www.lawsuit-information-center.com/2-billion-verdict-in-missouri-motivates-jj-to-settle-talcum-powder-lawsuits.html>

Niel, T., & Niel, T. (2025, November 21). 1 Reason Why Shares of Johnson & Johnson Are Surging This Month | The Motley Fool. The Motley Fool.

<https://www.fool.com/investing/2025/11/21/reason-why-shares-jnj-are-surging-november/>

Shah, K. (2025, December 22). J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play. Yahoo Finance. <https://finance.yahoo.com/news/j-j-stock-trading-above-162100123.html>